Kidney Dysfunction, Hepatic Impairment, and Lipid Metabolism Abnormalities in Patients with Precapillary Pulmonary Hypertension

被引:0
作者
Iancu, Dragos Gabriel [1 ,2 ,3 ]
Varga, Andreea [3 ,4 ]
Cristescu, Liviu [1 ,3 ]
Dumbrava, Robert Adrian [1 ,2 ]
Stoica, Florin [1 ,2 ]
Moldovan, Diana Andreea [1 ,3 ,5 ]
Suteu, Radu Adrian [5 ]
Tilea, Ioan [3 ,4 ]
机构
[1] GE Palade Univ Med Pharm Sci & Technol Targu Mures, Doctoral Sch, Targu Mures 540142, Romania
[2] Emergency Clin Cty Hosp, Dept Internal Med 2, Targu Mures 540042, Romania
[3] GE Palade Univ Med Pharm Sci & Technol Targu Mures, Fac Med, Targu Mures 540142, Romania
[4] Emergency Clin Cty Hosp, Dept Cardiol 2, Targu Mures 540042, Romania
[5] Emergency Inst Cardiovasc Dis & Transplantat, Dept Cardiol 1, Targu Mures 540136, Romania
关键词
pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension; kidney dysfunction; hepatic impairment; lipid metabolism abnormalities; ENDOTHELIN RECEPTOR ANTAGONISTS; SOLUBLE GUANYLATE-CYCLASE; RIGHT HEART-FAILURE; ARTERIAL-HYPERTENSION; THERAPEUTIC TARGET; DISEASE; PREVALENCE; MANAGEMENT; ASSOCIATION; CHOLESTEROL;
D O I
10.3390/diagnostics14161824
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pulmonary hypertension (PH) is a global health issue that has profound medical and research implications. Methods: This retrospective study examined changes in renal and liver function, as well as lipid metabolism, over a 12-month period in 49 adult patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). All cases were admitted, managed, and followed up with in the PH Center, County Emergency Clinical Hospital of Targu Mures, Romania. Results: Kidney dysfunction was observed in 12.24% of cases at baseline, decreasing to 8.16% at 12 months, and CTEPH patients were more affected. In particular, CTEPH patients exhibited an improvement in renal function, confirmed by an increase in their glomerular filtration rates. Hepatic impairment was present in 57.14% of subjects at baseline, declining to 42.86% at 12 months, with significant improvements noted in the PAH group. Lipid metabolic dysregulations were experienced by 22.45% of all patients at baseline, decreasing to 16.33% at 6 months, with a slow elevation to 24.49% at 12 months, but with no statistically significant differences. Pharmacological regimens were adjusted in accordance with the PH groups, a patient's functional and clinical response, and laboratory tests. Conclusions: Our results demonstrate the multi-organ damage in PH and the importance of individualized treatment approaches.
引用
收藏
页数:19
相关论文
共 62 条
[31]   Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment [J].
Kaufmann, Priska ;
Cruz, Hans G. ;
Krause, Andreas ;
Ulc, Ivan ;
Halabi, Atef ;
Dingemanse, Jasper .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (02) :369-379
[32]  
Khaybullina Diana, 2014, P T, V39, P749
[33]   Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension [J].
Khirfan, Ghaleb ;
Tejwani, Vickram ;
Wang, Xiaofeng ;
Li, Manshi ;
DiDonato, Joseph ;
Dweik, Raed A. ;
Smedira, Nicholas ;
Heresi, Gustavo A. .
PLOS ONE, 2018, 13 (05)
[34]   Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension [J].
Kopec, Grzegorz ;
Waligora, Marcin ;
Tyrka, Anna ;
Jonas, Kamil ;
Pencina, Michael J. ;
Zdrojewski, Tomasz ;
Moertl, Deddo ;
Stokwiszewski, Jakub ;
Zagozdzon, Pawel ;
Podolec, Piotr .
SCIENTIFIC REPORTS, 2017, 7
[35]   Current concepts in ischemic hepatitis [J].
Lightsey, Joseph M. ;
Rockey, Don C. .
CURRENT OPINION IN GASTROENTEROLOGY, 2017, 33 (03) :158-163
[36]   Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension [J].
Mohammadi, Asma ;
Matos, Wanessa F. ;
Intriago, Cesar ;
Thakkar, Keval ;
Jahan, Nasrin ;
Shah, Heeya ;
Nishu, Rifath I. ;
Marzban, Sima .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
[37]   Presence and Outcomes of Kidney Disease in Patients with Pulmonary Hypertension [J].
Navaneethan, Sankar D. ;
Wehbe, Edgard ;
Heresi, Gustavo A. ;
Gaur, Varun ;
Minai, Omar A. ;
Arrigain, Susana ;
Nally, Joseph V., Jr. ;
Schold, Jesse D. ;
Rahman, Mahboob ;
Dweik, Raed A. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (05) :855-863
[38]   Kidney dysfunction in patients with pulmonary arterial hypertension [J].
Nickel, N. P. ;
O'Leary, J. M. ;
Brittain, E. L. ;
Fessel, J. P. ;
Zamanian, R. T. ;
West, J. D. ;
Austin, E. D. .
PULMONARY CIRCULATION, 2017, 7 (01) :38-54
[39]   Liver abnormalities in pulmonary arterial hypertension [J].
Nickel, Nils P. ;
Galura, Gian M. ;
Zuckerman, Marc J. ;
Hakim, M. Nawar ;
Alkhateeb, Haider ;
Mukherjee, Debabrata ;
Austin, Eric D. ;
Heresi, Gustavo D. .
PULMONARY CIRCULATION, 2021, 11 (04)
[40]   Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension [J].
Nickel, Nils P. ;
Yuan, Ke ;
Dorfmuller, Peter ;
Provencher, Steeve ;
Lai, Yen-Chun ;
Bonnet, Sebastien ;
Austin, Eric D. ;
Koch, Carl D. ;
Morris, Alison ;
Perros, Frederic ;
Montani, David ;
Zamanian, Roham T. ;
Perez, Vinicio A. de Jesus .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (02) :148-157